Inhibikase Therapeutics, Inc. IKT
We take great care to ensure that the data presented and summarized in this overview for Inhibikase Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in IKT
Top Purchases
Top Sells
About IKT
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Insider Transactions at IKT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 21
2024
|
Arvind Kush |
BUY
Open market or private purchase
|
Direct |
145,000
+50.0%
|
$145,000
$1.37 P/Share
|
|
Oct 21
2024
|
Roberto Bellini |
BUY
Open market or private purchase
|
Indirect |
1,460,000
+50.0%
|
$1,460,000
$1.37 P/Share
|
|
Oct 21
2024
|
Amit Munshi |
BUY
Open market or private purchase
|
Indirect |
365,000
+50.0%
|
$365,000
$1.37 P/Share
|
|
Aug 16
2022
|
Milton H. Werner President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.09%
|
$0
$0.8 P/Share
|
|
May 27
2022
|
Milton H. Werner President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.09%
|
$0
$0.98 P/Share
|
|
May 20
2022
|
Milton H. Werner President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+0.19%
|
$0
$0.6 P/Share
|
|
May 19
2022
|
Joseph Frattaroli Cheif Financial Officer |
BUY
Open market or private purchase
|
Direct |
3,948
+7.59%
|
$0
$0.64 P/Share
|
|
Jan 03
2022
|
Milton H. Werner President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,853
+0.41%
|
$43,706
$2.02 P/Share
|
|
Nov 17
2021
|
Milton H. Werner President and CEO |
BUY
Open market or private purchase
|
Indirect |
23,589
+13.21%
|
$23,589
$1.96 P/Share
|
|
Aug 17
2021
|
Milton H. Werner President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
21,853
+0.41%
|
$43,706
$2.02 P/Share
|
|
May 14
2021
|
Milton H. Werner President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
16,918
-0.32%
|
$67,672
$4.59 P/Share
|
|
May 14
2021
|
Milton H. Werner President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
43,707
+0.82%
|
$0
$0.38 P/Share
|
|
Dec 28
2020
|
Joseph Frattaroli Cheif Financial Officer |
BUY
Conversion of derivative security
|
Indirect |
44,143
+50.0%
|
$441,430
$10.0 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.97M shares |
|---|